Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Gene therapy reverses muscular dystrophy in animal model

17.09.2002


Researchers have proven that gene therapy can reverse the pathological features of muscular dystrophy in an animal model. Before, gene therapy had only been able to prevent further muscle-wasting in mice. "We expect to build on these results in the continuing search for a way to treat a horrible disease. Our results indicate that gene therapy could be used not only to halt or prevent this disease, but also to restore normal muscle function in older patients," says Dr. Jeffrey S. Chamberlain, professor of neurology at the University of Washington School of Medicine in Seattle.



Chamberlain is the senior author of the paper describing the results, which will be published in the Proceedings of the National Academy of Sciences online Early Edition the week of Sept. 16 to 20.

Duchenne muscular dystrophy is an X-linked genetic disorder that strikes one of every 3,500 newborn boys. The genetic disorder means the body does not produce the dystrophin protein, which is necessary for the structural support of muscle. Without this protein, muscles weaken to the point where the victim cannot survive. There is no specific treatment against any form of muscular dystrophy, except for supportive measures, such as physical therapy, assistive technology and corrective surgery. Boys and men with the disorder usually die from respiratory failure before they can turn 25.


Researchers have been looking for many years for ways to introduce the dystrophin gene into the body of patients to replace the missing gene. In doing so, researchers have developed a strain of mice who lack the dystrophin gene. In the past, researchers have been able to insert the gene into newborn mice via adenoviral vectors. But those vectors have many viral properties, and results have been limited because adult mice and mice that have begun to develop symptoms of the disease developed a sharp host immune response that eliminated the therapeutic gene.

The results have also been limited because the dystrophin gene is large, and until now, there has not been a good way to deliver the entire gene and have it remain in the muscles of the mice. Last spring, Chamberlain and colleagues reported they were able to deliver a "micro" version of the dystrophin gene. Even the micro version appeared able to reverse the muscle-wasting process, but it was not as effective as the full gene.

However, in the Sept. 16 paper, Chamberlain and colleagues describe how they developed A stripped-down vectors that did not raise a host immune response and which delivered the full-length, muscle-specific dystrophin gene. They showed that the full gene could be delivered to muscles of young and old mice, even well after severe muscle damage had developed. Also, they showed that normal muscle function was restored to a level that directly correlated with the amount of the gene that was delivered.

"These results are extremely encouraging. We have shown that replacing the dystrophin gene will correct this disease, even in older animals. In future research, we hope to develop better methods to deliver the gene to all the muscles of the body, as currently we are limited to treating relatively small muscles. We believe these results also support the need to move forward with human clinical trials to assess the safety of these methods in patients," Chamberlain said.

The research was funded by grants from the National Institutes of Health, the Muscular Dystrophy Association and the Apex Foundation, a family foundation established by Bruce and Jolene McCaw. Other authors of the paper include Christiana DelloRusso, the lead author, of the UW Departments of Physiology and Neurology; Jeannine M. Scott, Dennis Hartigan-O’Connor and Robert W. Crawford of the Department of Neurology; former UW researchers Giovanni Salvatori, Catherine Barjot and Ann S. Robinson, and Susan V. Brooks of the University of Michigan.

Walter Neary | EurekAlert!
Further information:
http://www.washington.edu/

More articles from Health and Medicine:

nachricht UIC researchers find unique organ-specific signature profiles for blood vessel cells
18.02.2020 | University of Illinois at Chicago

nachricht Remdesivir prevents MERS coronavirus disease in monkeys
14.02.2020 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Freiburg researcher investigate the origins of surface texture

Most natural and artificial surfaces are rough: metals and even glasses that appear smooth to the naked eye can look like jagged mountain ranges under the microscope. There is currently no uniform theory about the origin of this roughness despite it being observed on all scales, from the atomic to the tectonic. Scientists suspect that the rough surface is formed by irreversible plastic deformation that occurs in many processes of mechanical machining of components such as milling.

Prof. Dr. Lars Pastewka from the Simulation group at the Department of Microsystems Engineering at the University of Freiburg and his team have simulated such...

Im Focus: Skyrmions like it hot: Spin structures are controllable even at high temperatures

Investigation of the temperature dependence of the skyrmion Hall effect reveals further insights into possible new data storage devices

The joint research project of Johannes Gutenberg University Mainz (JGU) and the Massachusetts Institute of Technology (MIT) that had previously demonstrated...

Im Focus: Making the internet more energy efficient through systemic optimization

Researchers at Chalmers University of Technology, Sweden, recently completed a 5-year research project looking at how to make fibre optic communications systems more energy efficient. Among their proposals are smart, error-correcting data chip circuits, which they refined to be 10 times less energy consumptive. The project has yielded several scientific articles, in publications including Nature Communications.

Streaming films and music, scrolling through social media, and using cloud-based storage services are everyday activities now.

Im Focus: New synthesis methods enhance 3D chemical space for drug discovery

After helping develop a new approach for organic synthesis -- carbon-hydrogen functionalization -- scientists at Emory University are now showing how this approach may apply to drug discovery. Nature Catalysis published their most recent work -- a streamlined process for making a three-dimensional scaffold of keen interest to the pharmaceutical industry.

"Our tools open up whole new chemical space for potential drug targets," says Huw Davies, Emory professor of organic chemistry and senior author of the paper.

Im Focus: Quantum fluctuations sustain the record superconductor

Superconductivity approaching room temperature may be possible in hydrogen-rich compounds at much lower pressures than previously expected

Reaching room-temperature superconductivity is one of the biggest dreams in physics. Its discovery would bring a technological revolution by providing...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

70th Lindau Nobel Laureate Meeting: Around 70 Laureates set to meet with young scientists from approx. 100 countries

12.02.2020 | Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

 
Latest News

Movement of a liquid droplet generates over 5 volts of electricity

18.02.2020 | Power and Electrical Engineering

Powering the future: Smallest all-digital circuit opens doors to 5 nm next-gen semiconductor

18.02.2020 | Information Technology

Studying electrons, bridging two realms of physics: connecting solids and soft matter

18.02.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>